Zepbound

Medicaid denials for Zepbound (tirzepatide) follow a predictable pattern, and the appeal follows a predictable counter-pattern.

Introduction Kaiser Permanente’s integrated HMO model means Zepbound® denials come from Kaiser’s internal Drug Coverage and Utilization Management committee, not from an outside PBM….

Humana’s business is heavily Medicare-weighted, which puts Zepbound in a tough spot on Part D plans.

Zepbound does not need a chemical taper. There is no withdrawal syndrome, no receptor downregulation that has to be unwound slowly.

Zepbound (tirzepatide) is available online through telehealth platforms in 2026.

Zepbound came off the FDA shortage list in December 2024, but the higher maintenance doses still hit periodic supply gaps in 2026.

Yes, Zepbound often causes increased urination, especially in the first few weeks.

The short version: Zepbound does not give you energy in the way a stimulant or thyroid pill does.

Introduction The honest answer is that no human data shows Zepbound® causes cancer, but the FDA boxed warning for thyroid C-cell tumors exists because…